Back to News
Market Impact: 0.35
Ascendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk
Source: Nasdaq
Capital Returns (Dividends / Buybacks)Healthcare & BiotechPatents & Intellectual Property
Ascendis Pharma's board authorized a share-repurchase program of up to $400 million. The commercial-stage biotech also said it will regain exclusive rights to develop, manufacture and commercialize TransCon technology-based products, strengthening its control over the platform and capital-return profile.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
ASND0.65
More News
- BioMarin to discontinue development of Voxzogo for Noonan syndrome in children
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Reliance Worldwide shares hit 1-year high on Brookfield’s $2.9 bln deal
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Write an Investment Memo with AI: A Decision-Record Template
- Best AI to Write Earnings Notes for Sell-Side Analysts